Compare Plug Power Inc (PLUG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plug Power Inc vs ResMed Inc. — how do they compare? Plug Power Inc trades at $1.75 (market cap $2.49B), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: ResMed Inc. is far larger — about 12.8× Plug Power Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Plug Power Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Plug Power Inc for 41 Days and ResMed Inc. for 51 Days on average.
| PLUG | RMD | |
|---|---|---|
Market Cap | $2.49B | $31.78B |
Volume | 47,846,349 | 1,128,382 |
Sector | Industrials | Health |
52-Week High | $4.14 | $277.88 |
52-Week Low | $1.73 | $182.82 |
Typical Hold Time | 41 Days | 51 Days |
Enterprise Value | $3.36B | $31.14B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Plug Power (PLUG) trades at $1.73, down 6.99% today, with a bearish technical signal and negative earnings momentum. The company continues to report significant losses with a -220.59% net income margin and negative cash flow, though recent electrolyzer supply agreements and international expansion provide some operational catalysts. Analyst sentiment is mixed with 44.73% buy ratings but a consensus price target of $3.13 suggesting 81% upside potential from current levels.
The stock faces substantial fundamental challenges with persistent losses and negative cash flow, but maintains analyst support due to its positioning in the growing green hydrogen market. Key risks include execution challenges in achieving profitability, high cash burn requiring continued financing, and competitive pressures in the clean energy sector. The current price near the analyst low target of $1.65 indicates limited downside protection.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
